# Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial

> **NCT04510597** · PHASE3 · RECRUITING · sponsor: **SWOG Cancer Research Network** · enrollment: 364 (estimated)

## Conditions studied

- Metastatic Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma
- Stage IV Renal Cell Cancer AJCC v8

## Interventions

- **PROCEDURE:** Cytoreductive Nephrectomy
- **DRUG:** Active Comparator

## Key facts

- **NCT ID:** NCT04510597
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-08
- **Primary completion:** 2033-07
- **Final completion:** 2033-07
- **Target enrollment:** 364 (ESTIMATED)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04510597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04510597, "Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04510597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*